Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2018 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, February 2018
Slide 1: Agilent Technologies Q1'18 Results Presentation
Agilent Technologies Q1’18 Results Presentation
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company’s goals, priorities, revenues, operating profit and operating margin, expected cash flow, growth opportunities, customer service and innovation plans, new
Slide 3: Agilent Results Q1'18
Agilent Results Q1'18 Scale and leading technology across Analytical Laboratories and Clinical & Dx markets Q1'18 Financial Metrics Q1’18 Headlines • Revenues: $1.21B, +9.7% y/y core(1)(2),+13.5% • Growth: Fourth consecutive quarter of double-digit reported (+0.4% M&A, +3.4% FX). Core growth Chemica
Slide 4: Life Sciences & Applied Markets Group (LSAG)
Life Sciences & Applied Markets Group (LSAG) Instrumentation and Informatics • Core revenue growth fueled by double-digit for Analytical Laboratories gains in major platforms led by Mass Spec and Cell Analysis, demand in Europe and China and broad strength across end-markets. • Operating Margin for
Slide 5: Agilent Cross Lab Group (ACG)
Agilent Cross Lab Group (ACG) • Continued strong revenue performance. Growth Analytical Laboratory Consumables and Services was balanced across services and consumables. China and Food led growth across all regions and major end-markets. • Operating Margin in the quarter was 21.6%(1)(2), up 130 bps
Slide 6: Diagnostics and Genomics Group (DGG)
Diagnostics and Genomics Group (DGG) Pathology, Genomics, and • Continued strong demand for pathology Nucleic Acid Manufacturing products and companion diagnostics services. China and Americas led regional gains. • Operating Margin for the quarter was 11.7%(1)(2), down 260 bps versus last year. NGS
Slide 7: Growth in a $21B Market – Q1'18 Results by End Market
Growth in a $21B Market – Q1'18 Results by End Market Broad gains highlighted by robust Chemical & Energy, Environmental & Forensics, and Academia & Government Analytical Laboratory End Markets Agilent Revenue by End Market (1) ▪ Q1'18 revenues: +11% y/y on core(2) basis ▪ Pharma & Biotech: Up 8% wi
Slide 8: Profitable Growth Plan
Agilent Profitable Growth Plan Recent Actions ▪ Delivering on “Agile Agilent” Initiatives • Multi-year program to increase efficiency and customer focus. Operating Margin up year-over-year – 12th consecutive quarter. ▪ Portfolio Investments and “Go-to-Market” Capability • Acquired Luxcel Biosciences
Slide 9: Strategy to Win
Agilent Strategy to Win Creating shareholder value ▪ Above Market Growth • Innovative, highly differentiated new products and solutions • Win enterprise lab-wide services & consumables - CrossLab • Accelerate bio-pharma penetration • Drive adoption of clinical genomics applications ▪ Aggressively ex
Slide 10: Q2'18 and FY18 Guidance and Forward-looking Considerations
Q2’18 and FY18 Guidance and Forward-looking Considerations Based on January 31, 2018 Exchange Rates FY18 Guidance • Revenue: $4.885B - $4.905B: growth at mid-point 5.5% core(4), 9.5% growth on unadjusted basis(1) (+0.2% M&A, +3.8% FX) • Operating Margin: 22.4% at mid-point or 22.6%(3) when adjusted